ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXAMINES VALUE ASSESSMENT OF TRANSFORMATIVE MEDICINES IN RARE DISEASES

Published Nov 1, 2016
Vienna, Austria—1 November 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) offered a thought-provoking issue panel, Valuing Transformative Medicines in Rare Diseases: Methods and Madness, at the Society’s 19th Annual European Congress in Vienna, Austria. Paul Hodgkins, PhD, Vice President, Vertex Pharmaceuticals, Boston, MA, USA moderated the session. Panelists included:
  • Ron Akehurst, DSc, Strategic Director, BresMed Health Solutions, Sheffield, UK
  • Alastair Kent, OBE, Director, Genetic Alliance UK, London, UK
  • Maarten Postma, PhD, Professor Pharmacoeconomics, Pharmacy Department, University of Groningen, Groningen, The Netherlands
Innovative treatments for rare diseases are often transformative for patients. This is especially true if the therapy is the first to treat a disease’s underlying cause, said moderator Paul Hodgkins. It can, however, be difficult to demonstrate clinical benefit and cost effectiveness due to a number of research challenges such as small sample sizes in clinical trials and the lack of good outcome measures. The question was raised, “Why should rare and/or ultra-rare conditions be treated any differently in health technology assessment than more common conditions?” Panelists examined the pros and cons of adhering to current methods and evidence standards versus employing alternative methodological approaches and data sources in rare disease treatment evaluation. Alastair Kent, OBE discussed the importance of patient values and priorities when developing rare disease treatments and outcome measures. ISPOR offers a number of working groups and resources related to this topic, including: Additional information on the ISPOR 19th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORVienna.

###

Related Stories

International Study Confirms Universally Applicable Framework for Defining Digital Health Interventions

Jan 21, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a comprehensive international study demonstrating that the PICOTS-ComTeC framework serves as an effective universal standard for defining patient-facing digital health interventions. The report, “Towards a Common Ground for Defining Digital Health Interventions, Mapping Digital Health Frameworks to PICOTS-ComTeC: An ISPOR Special Interest Group Report” was published in the January 2026 issue of Value in Health.

ISPOR Releases New 2026-2027 Top 10 HEOR Trends Report

Jan 20, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR) announced today the publication of its new “2026-2027 Top 10 HEOR Trends Report.” The Society publishes this report every two years as part of its horizon scanning and monitoring of the trends that affect healthcare decision making around the world.

ISPOR Announces New Executive Director for the ISPOR Institute for Healthcare Transformation

Jan 13, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced that Kelly Saldaña has been appointed as executive director for the ISPOR Institute for Healthcare Transformation.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×